Responses
Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
730 A phase I safety and tolerability study of VAXinia (CF33-hNIS), a novel chimeric oncolytic poxvirus, administered intratumorally or intravenously in adults with metastatic or advanced solid tumors
Compose a Response to This Article
Other responses
No responses have been published for this article.
